임뉴셀(ICCC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $10.05 (-7.80%), 시가총액 $0.08B, 52주 범위 $4.56 ~ $8.92.
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is masti
임뉴셀의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
임뉴셀의 현재 주가는 $10.05 (-7.80%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
임뉴셀의 시가총액은 약 $0.08B입니다.
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.